Vol 94, No 3 (2023)
Research paper
Published online: 2022-02-15

open access

Page views 3108
Article views/downloads 1041
Get Citation

Connect on Social Media

Connect on Social Media

Is there association between thyroid stimulating hormone levels and the four phenotypes in polycystic ovary syndrome?

Hyun Joo Lee1, Hyun Nyung Jo2, Hye Kyung Noh3, So Hee Kim1, Jong Kil Joo1
Pubmed: 35315007
Ginekol Pol 2023;94(3):203-210.


Objectives: The aim of this study was to determine whether the incidence of subclinical hypothyroidism (SCH) is higher in polycystic ovary syndrome (PCOS) group than the control group. Additionally, the study investigated whether serum thyroid stimulating hormone (TSH) level is associated with various clinical parameters of PCOS regarding different phenotypes of the disease.

Material and methods: This retrospective, case-control study included 329 PCOS patients and 162 control women who were aged between 20 and 42 years and visited the Gynecology outpatient clinic in Pusan National University Hospital from January 2014 to December 2017. PCOS patients were further classified according to their phenotypes: phenotype A as the combination of all hyperandrogenism (HA), ovulatory dysfunction (OD), and polycystic ovarian morphology (PCOM); phenotype B as the combination of HA and OD; phenotype C as the combination of HA and PCOM; and finally, phenotype D as the combination of OD and PCOM. Laboratory blood tests included follicle stimulating hormone (FSH), luteinizing hormone (LH), TSH and anti-mullerian hormone (AMH). The ovarian volume was calculated using three diameters by gynecologic ultrasonography.

Results: Serum TSH level was significantly higher in PCOS patients than in the control group after adjusting for age and body mass index (BMI). Serum TSH level was not related to HA and OD, but its significant association with PCOM was confirmed in comparative analysis in quartiles. The proportion of phenotype A patients increased as serum TSH level increased, while the proportion of phenotype B and D decreased. Phenotype C stayed relatively consistent with varying TSH levels.

Conclusions: More numbers of patients showed elevated TSH level satisfying SCH diagnosis in PCOS group than the control group. In addition, a significant correlation between serum TSH level and different PCOS phenotypes has been observed; especially, PCOS patients with phenotype A, which displays all of HA, OD, and PCOM, tended to have the higher TSH levels than the PCOS patients with other phenotypes, requiring proper and thorough evaluation for potential endocrine disparity and according to management in such patient group.

Article available in PDF format

View PDF Download PDF file


  1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
  2. de Medeiros SF, de Medeiros MA, Ormond CM, et al. Subclinical hypothyroidism impact on the characteristics of patients with polycystic ovary syndrome. A meta-analysis of observational studies. Gynecol Obstet Invest. 2018; 83(2): 105–115.
  3. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999; 84(6): 1897–1899.
  4. Morales AJ, Laughlin GA, Bützow T, et al. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 1996; 81(8): 2854–2864.
  5. Medeiros SF, Barbosa JS, Yamamoto MM. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women. J Obstet Gynaecol Res. 2015; 41(2): 254–263.
  6. Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype and adiposity impact. Trends Endocrinol Metab. 2015; 26(3): 136–143.
  7. Teede HJ, Misso ML, Deeks AA, et al. Guideline Development Groups. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust. 2011; 195(6): S65–112.
  8. Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013; 28(3): 777–784.
  9. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6): 774–800.
  10. Mueller A, Schöfl C, Dittrich R, et al. Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. Hum Reprod. 2009; 24(11): 2924–2930.
  11. Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. The Journal of Clinical Endocrinology & Metabolism. 2006; 91(11): 4237–4245.
  12. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004; 59(2): 141–154.
  13. Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009; 160(5): 785–790.
  14. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf). 1999; 50(5): 655–659.
  15. Ding X, Yang L, Wang J, et al. Subclinical hypothyroidism in polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018; 9: 700.
  16. Benetti-Pinto CL, Berini Piccolo VR, Garmes HM, et al. Subclinical hypothyroidism in young women with polycystic ovary syndrome: an analysis of clinical, hormonal, and metabolic parameters. Fertil Steril. 2013; 99(2): 588–592.
  17. Calvar CE, Bengolea SV, Deutsch SI, et al. [High frequency of thyroid abnormalities in polycystic ovary syndrome]. Medicina (B Aires). 2015; 75(4): 213–217.
  18. Singla R, Gupta Y, Khemani M, et al. Thyroid disorders and polycystic ovary syndrome: An emerging relationship. Indian Journal of Endocrinology and Metabolism. 2015; 19(1): 25.
  19. Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and Sterility. 2016; 106(1): 6–15.
  20. Sinha U, Sinharay K, Saha S, et al. Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. Indian Journal of Endocrinology and Metabolism. 2013; 17(2): 304.
  21. Janssen OE, Mehlmauer N, Hahn S, et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004; 150(3): 363–369.
  22. Dewailly D, Hieronimus S, Mirakian P, et al. Polycystic ovary syndrome (PCOS). Ann Endocrinol (Paris). 2010; 71(1): 8–13.
  23. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003; 79(1): 91–95.
  24. Mimoto M, Oyler J, Davis A. Evaluation and treatment of hirsutism in premenopausal women. JAMA. 2018; 319(15): 1613.
  25. Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007; 2(2): 189–199.
  26. Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol. 2018; 4(2): 56–71.
  27. Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014; 211(1): 59.e1–59.e8.
  28. Kuroda K, Uchida T, Nagai S, et al. Elevated serum thyroid-stimulating hormone is associated with decreased anti-Müllerian hormone in infertile women of reproductive age. J Assist Reprod Genet. 2015; 32(2): 243–247.
  29. Malini NA, Roy George K. Evaluation of different ranges of LH:FSH ratios in polycystic ovarian syndrome (PCOS) - Clinical based case control study. Gen Comp Endocrinol. 2018; 260: 51–57.
  30. Cai J, Zhang Yi, Wang Y, et al. High thyroid stimulating hormone level is associated with hyperandrogenism in euthyroid polycystic ovary syndrome (PCOS) women, independent of age, BMI, and thyroid autoimmunity: a cross-sectional analysis. Front Endocrinol (Lausanne). 2019; 10: 222.
  31. Han YS, Lee AhR, Song HK, et al. Ovarian volume in Korean women with polycystic ovary syndrome and its related factors. J Menopausal Med. 2017; 23(1): 25–31.
  32. Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord. 2018; 17(2): 277–285.
  33. Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18(6): 618–637.
  34. Saadia Z. Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women. Medical Archives. 2020; 74(4): 289.
  35. Yu Q, Wang JB. Subclinical hypothyroidism in PCOS: impact on presentation, insulin resistance, and cardiovascular risk. Biomed Res Int. 2016; 2016: 2067087.
  36. Flood DEK, Fernandino JI, Langlois VS. Thyroid hormones in male reproductive development: evidence for direct crosstalk between the androgen and thyroid hormone axes. Gen Comp Endocrinol. 2013; 192: 2–14.
  37. Denver RJ. Several hypothalamic peptides stimulate in vitro thyrotropin secretion by pituitaries of anuran amphibians. Gen Comp Endocrinol. 1988; 72(3): 383–393.
  38. Duarte-Guterman P, Navarro-Martín L, Trudeau VL. Mechanisms of crosstalk between endocrine systems: regulation of sex steroid hormone synthesis and action by thyroid hormones. Gen Comp Endocrinol. 2014; 203: 69–85.